# A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)

> **NCT04320316** · PHASE4 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 1 (actual)

## Conditions studied

- Epidermal Nevus Syndrome

## Interventions

- **DRUG:** Crysvita (burosumab-twza) Treatment

## Key facts

- **NCT ID:** NCT04320316
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-31
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-08-31
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2022-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04320316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04320316, "A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04320316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*